Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Secto

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweigh

What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said on October 1, 2026, it entered the

Central Pacific Bank Trust Division raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemi

The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQ

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Thursday shared clinical trial results for two inves

Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle pr

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammatio

Rigel Pharmaceuticals (NASDAQ: RIGL - Get Free Report) and Regeneron Pharmaceuticals (NASDAQ: REGN -

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acti

Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and r

Regeneron and Sanofi announced a strategic expansion of their antibody collaboration, targeting IL-4

Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE

LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is

In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide t

Regeneron and Sanofi expand their 20-year antibody collaboration with a $1 billion upfront payment a

Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collabo

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified expos

Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-gene

Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold

The companies will share development and commercialization costs as well as potential future profits

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regenero

French drugmaker ​Sanofi said on Thursday it ‌would pay US partner Regeneron $1 billion upfront and

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regenero

Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology a

An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk'

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has earned a consensus rating of "M

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sect

Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with

Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenku

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55%

HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59%

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17%

Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven

Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after hi

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69%

China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s

https://www.newswire.ca/news-releases/libtayo-r-cemiplimab-for-injection-receives-health-canada-appr

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and r